These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


119 related items for PubMed ID: 1834022

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin.
    Suzuki F, Pollard RB, Uchimura S, Munakata T, Maeda H.
    Cancer Res; 1990 Jul 01; 50(13):3897-904. PubMed ID: 2141295
    [Abstract] [Full Text] [Related]

  • 9. Additive effects of bleomycin and neocarzinostatin on degradation of DNA, inhibition of DNA polymerase beta, and cell growth.
    Müller WE, Maidhof A, Arendes J, Geurtsen W, Zahn RK, Schmidseder R.
    Cancer Res; 1979 Sep 01; 39(9):3768-73. PubMed ID: 89904
    [Abstract] [Full Text] [Related]

  • 10. Neocarzinostatin-induced DNA strand scission and subsequent cell cycle traverse in HeLa S3 cells.
    Berry DE, Collins JM.
    Cancer Res; 1980 Jul 01; 40(7):2405-10. PubMed ID: 6446380
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Antitumor activities of oily suspended YM881 (SMANCS) against VX2 carcinoma].
    Kimura M, Konno T, Ohtsuka N, Mizumachi R, Oda T.
    Gan To Kagaku Ryoho; 1989 Jun 01; 16(6):2183-8. PubMed ID: 2544148
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Anti-tumor activity of zinostatin stimalamer (YM 881) examined by human hepatoma cells in vitro and VX2 liver tumor in vivo].
    Tanaka S, Fujihara A, Yamamoto M, Asano M, Ida H, Ohmi Y, Kitazaki T, Kikuchi Y, Yoshida S, Okamiya H.
    Gan To Kagaku Ryoho; 1994 Feb 01; 21(2):219-26. PubMed ID: 8311492
    [Abstract] [Full Text] [Related]

  • 15. Effect of poly(adenosine diphosphate-ribose) polymerase inhibitors on neocarzinostatin-induced G2 delay in HeLa-S3 cells.
    Iseki S, Mori T.
    Cancer Res; 1985 Sep 01; 45(9):4224-8. PubMed ID: 2992774
    [Abstract] [Full Text] [Related]

  • 16. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH.
    Oda T, Sato F, Maeda H.
    J Natl Cancer Inst; 1987 Dec 01; 79(6):1205-11. PubMed ID: 2961908
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture.
    Oda T, Sato F, Yamamoto H, Akagi M, Maeda H.
    Anticancer Res; 1989 Dec 01; 9(2):261-5. PubMed ID: 2526613
    [Abstract] [Full Text] [Related]

  • 18. Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin.
    Hartsell TL, Yalowich JC, Ritke MK, Martinez AJ, Schor NF.
    J Pharmacol Exp Ther; 1995 Oct 01; 275(1):479-85. PubMed ID: 7562588
    [Abstract] [Full Text] [Related]

  • 19. Changes in cellular components of spleen and lymph node cells and the effector cells responsible for Meth A tumor eradication induced by zinostatin stimalamer.
    Masuda E, Maeda H.
    Cancer Res; 1996 Apr 15; 56(8):1868-73. PubMed ID: 8620506
    [Abstract] [Full Text] [Related]

  • 20. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells.
    Bañuelos A, Reyes E, Ocadiz R, Alvarez E, Moreno M, Monroy A, Gariglio P.
    J Pharmacol Exp Ther; 2003 Aug 15; 306(2):671-80. PubMed ID: 12750435
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.